How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in
2025? A position paper from the EORTC-GITCG gastro-esophageal
task force

J 2025

How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force

CHRISTELLE, de la Fouchardiere; Antonella CAMMAROTA; Magali SVRCEK; Maria ALSINA; Tania FLEITAS-KANONNIKOFF et. al.

Základní údaje

Originální název

How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force

Autoři

CHRISTELLE, de la Fouchardiere; Antonella CAMMAROTA; Magali SVRCEK; Maria ALSINA; Tania FLEITAS-KANONNIKOFF; Radka LORDICK OBERMANNOVÁ (203 Česká republika, domácí); Anna Dorothea WAGNER; Dominic Yap Wei TING; Diana ENEA; Angelica PETRILLO a Elizabeth C SMYTH

Vydání

CANCER TREATMENT REVIEWS, OXFORD, ELSEVIER SCI LTD, 2025, 0305-7372

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 9.600 v roce 2023

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.ctrv.2025.102890

UT WoS

001426329600001

EID Scopus

2-s2.0-85217255683

Klíčová slova anglicky

dMMR/MSI gastro-esophageal adenocarcinoma; Gastric cancer; Esophageal cancer; MSI; Immune checkpoint inhibitors

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 4. 2025 09:23, Mgr. Tereza Miškechová

Anotace

V originále

In less than a decade, immune checkpoint inhibitors (ICIs) have transformed the management of mismatch repair-deficient (dMMR) and microsatellite instability-high (MSI) cancers. However, beyond colorectal cancer (CRC), much of the evidence is mostly derived from non-randomized phase II studies or post-hoc analyses of broader clinical trials. dMMR/MSI tumours represent a specific subgroup of gastro-esophageal adenocarcinomas (GEA), accounting for approximately 9 % of cases, with a higher prevalence in early-stage compared to advanced-stage disease and older female patients. These tumours are predominantly sporadic, often linked to MLH1 promoter methylation, and rarely exhibit HER2 overexpression/ERBB2 amplification or other oncogenic drivers. The treatment landscape for early stage dMMR/MSI GEA is likely to change substantially soon, as ICIs have shown high pathological complete response (pCR) rates in small phase II trials, raising questions on optimisation of neoadjuvant therapy, and paving the way for organ preservation. The standard of treatment for untreated patients with advanced dMMR/MSI GEA is chemotherapy + ICI irrespectively of PDL-1 status. However, the role of chemotherapy-free regimen consisting of CTLA-4 plus PD-1 inhibitors remains

Citovat

CHRISTELLE, de la Fouchardiere; Antonella CAMMAROTA; Magali SVRCEK; Maria ALSINA; Tania FLEITAS-KANONNIKOFF; Radka LORDICK OBERMANNOVÁ; Anna Dorothea WAGNER; Dominic Yap Wei TING; Diana ENEA; Angelica PETRILLO a Elizabeth C SMYTH. How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force. CANCER TREATMENT REVIEWS. OXFORD: ELSEVIER SCI LTD, 2025, roč. 134, March 2025, s. 1-14. ISSN 0305-7372. Dostupné z: https://dx.doi.org/10.1016/j.ctrv.2025.102890.

@article{2488665,
   author = {Christelle, de la Fouchardiere and Cammarota, Antonella and Svrcek, Magali and Alsina, Maria and FleitasandKanonnikoff, Tania and Lordick Obermannová, Radka and Wagner, Anna Dorothea and Ting, Dominic Yap Wei and Enea, Diana and Petrillo, Angelica and Smyth, Elizabeth C},
   article_location = {OXFORD},
   article_number = {March 2025},
   doi = {http://dx.doi.org/10.1016/j.ctrv.2025.102890},
   keywords = {dMMR/MSI gastro-esophageal adenocarcinoma; Gastric cancer; Esophageal cancer; MSI; Immune checkpoint inhibitors},
   language = {eng},
   issn = {0305-7372},
   journal = {CANCER TREATMENT REVIEWS},
   title = {How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force},
   url = {https://www.sciencedirect.com/science/article/pii/S030573722500012X?via%3Dihub},
   volume = {134},
   year = {2025}
}

TY  - JOUR
ID  - 2488665
AU  - Christelle, de la Fouchardiere - Cammarota, Antonella - Svrcek, Magali - Alsina, Maria - Fleitas-Kanonnikoff, Tania - Lordick Obermannová, Radka - Wagner, Anna Dorothea - Ting, Dominic Yap Wei - Enea, Diana - Petrillo, Angelica - Smyth, Elizabeth C
PY  - 2025
TI  - How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force
JF  - CANCER TREATMENT REVIEWS
VL  - 134
IS  - March 2025
SP  - 1-14
EP  - 1-14
PB  - ELSEVIER SCI LTD
SN  - 03057372
KW  - dMMR/MSI gastro-esophageal adenocarcinoma
KW  - Gastric cancer
KW  - Esophageal cancer
KW  - MSI
KW  - Immune checkpoint inhibitors
UR  - https://www.sciencedirect.com/science/article/pii/S030573722500012X?via%3Dihub
N2  - In less than a decade, immune checkpoint inhibitors (ICIs) have transformed the management of mismatch repair-deficient (dMMR) and microsatellite instability-high (MSI) cancers. However, beyond colorectal cancer (CRC), much of the evidence is mostly derived from non-randomized phase II studies or post-hoc analyses of broader clinical trials. dMMR/MSI tumours represent a specific subgroup of gastro-esophageal adenocarcinomas (GEA), accounting for approximately 9 % of cases, with a higher prevalence in early-stage compared to advanced-stage disease and older female patients. These tumours are predominantly sporadic, often linked to MLH1 promoter methylation, and rarely exhibit HER2 overexpression/ERBB2 amplification or other oncogenic drivers. The treatment landscape for early stage dMMR/MSI GEA is likely to change substantially soon, as ICIs have shown high pathological complete response (pCR) rates in small phase II trials, raising questions on optimisation of neoadjuvant therapy, and paving the way for organ preservation. The standard of treatment for untreated patients with advanced dMMR/MSI GEA is chemotherapy + ICI irrespectively of PDL-1 status. However, the role of chemotherapy-free regimen consisting of CTLA-4 plus PD-1 inhibitors remains
ER  -

CHRISTELLE, de la Fouchardiere; Antonella CAMMAROTA; Magali SVRCEK; Maria ALSINA; Tania FLEITAS-KANONNIKOFF; Radka LORDICK OBERMANNOVÁ; Anna Dorothea WAGNER; Dominic Yap Wei TING; Diana ENEA; Angelica PETRILLO a Elizabeth C SMYTH. How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force. \textit{CANCER TREATMENT REVIEWS}. OXFORD: ELSEVIER SCI LTD, 2025, roč.~134, March 2025, s.~1-14. ISSN~0305-7372. Dostupné z: https://dx.doi.org/10.1016/j.ctrv.2025.102890.

Přehled o publikaci